The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2025
Filed:
Sep. 19, 2023
Applicant:
C4 Therapeutics, Inc., Watertown, MA (US);
Inventors:
Roger Norcross, Basel, CH;
Annick Goergler, Basel, CH;
Fabian Dey, Basel, CH;
Eric Andre Kusznir, Basel, CH;
Assignee:
C4 Therapeutics, Inc., Watertown, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 235/26 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 417/10 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); C07D 235/26 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 417/10 (2013.01); C07D 487/08 (2013.01);
Abstract
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.